Lenalidomide, dexamethasone (DrugBank: Lenalidomide, Dexamethasone)
25 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
13 | 多発性硬化症/視神経脊髄炎 | 0 |
14 | 慢性炎症性脱髄性多発神経炎/多巣性運動ニューロパチー | 0 |
16 | クロウ・深瀬症候群 | 1 |
28 | 全身性アミロイドーシス | 2 |
35 | 天疱瘡 | 0 |
46 | 悪性関節リウマチ | 0 |
53 | シェーグレン症候群 | 0 |
63 | 特発性血小板減少性紫斑病 | 0 |
64 | 血栓性血小板減少性紫斑病 | 0 |
65 | 原発性免疫不全症候群 | 0 |
70 | 広範脊柱管狭窄症 | 0 |
74 | 下垂体性PRL分泌亢進症 | 0 |
75 | クッシング病 | 0 |
81 | 先天性副腎皮質酵素欠損症 | 0 |
83 | アジソン病 | 0 |
84 | サルコイドーシス | 0 |
90 | 網膜色素変性症 | 0 |
96 | クローン病 | 0 |
97 | 潰瘍性大腸炎 | 0 |
162 | 類天疱瘡(後天性表皮水疱症を含む。) | 0 |
222 | 一次性ネフローゼ症候群 | 0 |
235 | 副甲状腺機能低下症 | 0 |
283 | 後天性赤芽球癆 | 0 |
296 | 胆道閉鎖症 | 0 |
299 | 嚢胞性線維症 | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01816620 (ClinicalTrials.gov) | March 2014 | 14/3/2013 | Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS Syndrome | An Open-label Phase II Study to Determine the Efficacy and Safety of Lenalidomide Plus Dexamethasone (LDex) in Patients With Newly Diagnosed POEMS Syndrome | POEMS Syndrome | Drug: Lenalidomide, Dexamethasone | Peking Union Medical College Hospital | Celgene Corporation | Completed | 18 Years | N/A | All | 41 | Phase 2 | China |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03252600 (ClinicalTrials.gov) | August 25, 2017 | 24/7/2017 | Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis | A Randomized Phase 2 Trial of Lenalidomide/ Dexamethasone/ Elotuzumab +/- Cyclophosphamide Followed by Lenalidomide/ Dexamethasone/Elotuzumab Maintenance as Second-Line Therapy for Patients With Relapsed AL Amyloidosis | Recurrent Primary Amyloidosis | Drug: Cyclophosphamide;Drug: Dexamethasone;Biological: Elotuzumab;Other: Laboratory Biomarker Analysis;Drug: Lenalidomide;Other: Pharmacological Study | Barbara Ann Karmanos Cancer Institute | National Cancer Institute (NCI);Bristol-Myers Squibb;Multiple Myeloma Research Consortium | Recruiting | 18 Years | N/A | All | 53 | Phase 2 | United States |
2 | NCT00981708 (ClinicalTrials.gov) | February 2008 | 19/9/2009 | Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL) | A Phase I/II Trial of Lenalidomide Combined With Cyclophosphamide and Intermediate Dose Dexamethasone in Patients With Primary (AL) Systemic Amyloidosis | Amyloidosis | Drug: Lenalidomide, Dexamethasone and Cyclophosphamide | University of Athens | Hellenic Cooperative Oncology Group | Active, not recruiting | 18 Years | N/A | Both | 37 | Phase 1;Phase 2 | Greece |